Objectives. Patient Controlled Analgesia (PCA) Management in the Seriously Ill. Discuss principles for opioid dosing and titration for acute pain

Size: px
Start display at page:

Download "Objectives. Patient Controlled Analgesia (PCA) Management in the Seriously Ill. Discuss principles for opioid dosing and titration for acute pain"

Transcription

1 Patient Controlled Analgesia (PCA) Management in the Seriously Ill Jeanie Youngwerth, MD University of Colorado School of Medicine Associate Professor of Medicine, Hospitalist Associate Director, Colorado Palliative Medicine Fellowship Director, Palliative Care Program I have no financial relationships to disclose Objectives Discuss principles for opioid dosing and titration for acute pain Apply equianalgesic opioid conversions Describe adjustments for opioids in the setting of renal/liver failure and the elderly

2 Methadone Does not follow regular opioid principles! Recommend consulting Palliative Care or Pain Service for patients in acute pain crisis who are on Methadone Bruera: JPM Which of the following has not been shown to improve pain? 1. Laughter 2. Music 3. Maternal kisses for childhood boo-boos 4. Profanity Dunbar: Proc R Soc 2012; Pulvers: Addict Beh 2012; Mitchell: Europ J Pian 2006; SMACK: J of Eval Clin Pract 2015; Stephens: NeuroReport 2009; Stephens: Journal of Pain Which of the following has not been shown to improve pain? 1. Laughter 2. Music 3. Maternal kisses for childhood boo-boos 4. Profanity Dunbar: Proc R Soc 2012; Pulvers: Addict Beh 2012; Mitchell: Europ J Pian 2006; SMACK: J of Eval Clin Pract 2015; Stephens: NeuroReport 2009; Stephens: Journal of Pain 2011.

3 Tolerance Which patient is considered to be opioid tolerant? Oxycodone SR 20 mg po BID for 1 week Morphine IR 15 mg po TID for 2 weeks Fentanyl patch 12 mcg/hr TD q72 hours for 3 weeks All of the above Which patient is considered to be opioid tolerant? Oxycodone SR 20 mg po BID for 1 week

4 Opioid Tolerance Morphine 60 mg po daily Oxycodone 30 mg po daily Hydromorphone 8 mg po daily Fentanyl 25 mcg/hr TD Oxymorphone 25 mg po daily v1.0. Pain Case Study 47 y/o M with metastatic neuroendocrine tumor Oxycodone SR 80 mg po BID Hydromorphone IR 4 mg po q 4 hrs prn pain 6 tablets a day (past 10 days) Acute pain crisis from tumor burden Cr 0.7; LFTs WNL Put on PCA overnight by moonlighter PCA Errors #1 improper dose/quantity US Pharmacopeia 2004; Hicks: Am J Health Syst Pharm 2008.

5 Opioid Conversions Equianalgesic Dosing 1 Calculate total 24 hour total opioid dose 2 Convert to 24 hour new opioid equivalent 3 Adjust by 50-75% for incomplete cross tolerance 4 Triple check calculations 5 Constipation prophylaxis! EPEC Module ; v1.0; NCCN: Adult Cancer Pain v Incomplete Cross Tolerance v1.0. Incomplete Cross Tolerance When switching from one opioid to another Start the new opioid at 50-75% of the equianalgesic dose 60% good generalization Pasternak: Trends in Pharm Sciences 2001; Ballantyne: NEJM 2003; Mehta: Anaesth 2006; v1.0; NCCN: Adult Cancer Pain v

6 * Pain Pearl * Adjust for incomplete cross tolerance 60% calculated dose Opioid Conversions Equianalgesic Dosing Current Opioid = Total 24 hour Current Opioid New Opioid Total 24 hour New Opioid (X) Choice of Opioid What is considered the gold standard opioid? Grass: Anesth Analg 2005; Ripamonte: Annals of Onc 2012.

7 S S Pain Case Study 1. Calculate total 24 hour opioid dose Oxycodone SR 160 mg / day + Hydromorphone IR 24 mg / day TDD = Morphine X mg IV / day Avoid Mixing Opioids é risk for confusion and mistakes by patients and providers SIMPLIFY Morphine SR + Morphine IR prn NCCN: Adult Cancer Pain v

8 Pain Case Study 2. Convert to 24 hour new opioid equivalent Current Opioid New Opioid = Total 24 hour Current Total 24 hour New (X) Oxycodone 20 mg po Morphine 10 mg IV = Oxycodone 160 mg/day po Morphine IV X X = Morphine 80 mg IV/day Pain Case Study 2. Convert to 24 hour new opioid equivalent Current Opioid New Opioid = Total 24 hour Current Total 24 hour New (X) Hydrom 7.5 mg po Morphine 10 mg IV = Hydrom 24 mg/day po Morphine IV X X = Morphine 32 mg IV/day Pain Case Study 3. Adjust by 60% for incomplete x- tolerance Morphine = 112 mg IV / day X 0.6 = Morphine 67 mg IV / day

9 4. Triple check calculations 5. Constipation prophylaxis! -Senna 2 tabs po BID Pain Case Study Hawley: JPSM 2008; Librach: JPSM 2010; Tarumi: JPSM Pain Case Study Morphine 67 mg IV / day PCA settings? PCA Parameters Basal Demand Lockout PCA Initiation FIRST ask yourself Opioid tolerant or not???

10 PCA Basal Rate Tolerant Convert 24 hour total opioid requirement to hourly rate (by equianalgesic dosing) Naive No basal rate é respiratory depression No ê pain scores Grass: Anesth Analg PCA Demand Dose Tolerant 50% of the basal rate (50-100%) Naive? Sidebotham: JPSM 1997; Krenn: Euro J Pain 2001; Macintrye: Br J Anaesth 2001; Didem: Can J Anesth 2003; Lehmann: JPSM 2005; Grass: Anesth Analg 2005; Herr: Iowa City Guideline Summary NGC PCA Demand Dose- Opioid Naive

11 Morphine Demand Dose 2 mg Opioid Naive 0.5 mg 1 mg Owen: Anaesth 1989; Sidebotham: JPSM Morphine Demand Dose Outcome Opioid Naive 1 mg Optimal balance Owen: Anaesth 1989; Sidebotham: JPSM PCA Demand Dose Tolerant Naive 50% of the basal rate (50-100%) Morphine 1 mg IV equivalent Sidebotham: JPSM 1997; Krenn: Euro J Pain 2001; Macintrye: Br J Anaesth 2001; Didem: Can J Anesth 2003; Lehmann: JPSM 2005; Grass: Anesth Analg 2005; Herr: Iowa City Guideline Summary NGC

12 PCA Lockout Time Based on time to peak effect IV: 8-10 min Plasma Concentration Cmax SC / IM: min PO / PR: min Time Half-life (t1/2) PCA Lockout Time Morphine 7 vs 11 minutes Fentanyl 5 vs 8 minutes No difference in pain, anxiety or side effects Ginsberg: Pain 1995.

13 PCA Lockout Time 10 minutes is a standard interval Ginsberg: Pain 1995; Macintrye: Br J Anaesth 2001; Walder: Acta Anaesthesiol Scand 2001; Grass: Anesth Analg 2005; Craft: Proc Bayl Univ Med Cent PCA Nurse Initiated Bolus Up to twice the demand dose Grass: Anesth Analg 2005; Craft: Proc Bayl Univ Med Cent Morphine 67 mg IV / day 24 hrs = 2.8 mg/hr Pain Case Study Basal 3 mg/hr Demand dose 1.5 mg Lockout time 10 min Nurse-bolus 3 mg

14 Summary: Opioid Naïve PCA Dosing (initial) Drug Basal Demand Lockout Nurse- Bolus Morphine X 1 mg 10 min 2 mg Hydromorphone X 0.2 mg 10 min 0.4 mg Fentanyl X 10 mcg 10 min 20 mcg SD Patient Safety Taskforce: Tool Kit: PCA Guidelines of Care Summary: Opioid Tolerant PCA Dosing Drug Basal Demand Lockout Nurse Bolus Morphine Convert 24 hr Hydromorphone total opioid Fentanyl requirement to hourly rate 50% (100%) basal rate 10 min 2x demand dose Nurse calls 3 hours later for patient with severe pain. What is the best next step when titrating the PCA for acute pain control? 3/1.5/10 1. Increase basal rate to 4 mg/hr 2. Increase demand dose to 3 mg 3. Decrease lockout time to 6 minutes 4. Opioid rotation to PCA IV Fentanyl 5. Add Oxycodone/Acetaminophen 5/ tablet oral q4 hours prn

15 Nurse calls 3 hours later for patient with severe pain. What is the best next step when titrating the PCA for acute pain control? 3/1.5/10 1. Increase basal rate to 4 mg/hr 2. Increase demand dose to 3 mg 3. Decrease lockout time to 6 minutes 4. Opioid rotation to PCA IV Fentanyl 5. Add Oxycodone/Acetaminophen 5/ tablet oral q4 hours prn Acute control Opioid Titration IR / prn Demand dose Chronic control SR / scheduled Basal rate Hanks: British J Cancer 2001; Grass: Anesth Analg 2005; NCCN Adult Cancer Pain V * Pain Pearl * Titrate the demand dose for acute pain

16 PCA Demand Dose Titration Practically reevaluate in 1 hour Can change every minutes if needed Opioid Titration Pain Severity Increase Dose Up To Mild 25% Moderate 50% Severe 100% EPEC Module ; NCCN Adult Cancer Pain V

17 PCA Basal Rate Titration Every 24 hours reasonable 8-24 hours to achieve steady state Avoid changing more frequently than q 8 hrs EPEC Module ; APS PCA Basal Rate Titration Dose based on Patient pain rating Your assessment Daily trend of 24 hr requirements Summary: PCA Titration Basal Rate Consider change daily based on 24 hour use Demand Dose (acute pain control) é 25% mild pain é 50% moderate é 100% severe Lockout 10 minutes

18 PCA to Oral Opioids Once stable opioid requirements for ~2 days TDD from PCA to calculate equianalgesic oral dose of new opioid Patient using TDD Morphine 130 mg IV / day Pain Case Study PCA to Oral Opioid Current Opioid New Opioid = Total 24 hour Current Total 24 hour New (X) Morphine 10 mg IV Morphine 30 mg po = Morphine 130 mg/day IV Morphine po X X = Morphine 390 mg po/day (no x-tolerance needed) Pain Case Study PCA to Oral Opioid X = Morphine 390 mg po/day Morphine ER 200 mg po BID Breakthrough pain (BTP)? 1. Oxycodone / Acetaminophen 5/ tab po q4 hrs prn 2. Oxycodone IR 10 mg po q 2 hrs prn 3. Morphine IR 45 mg po q 1 hrs prn 4. Hydromorphone IR 4 mg po q 4 hrs prn

19 Pain Case Study PCA to Oral Opioid X = Morphine 390 mg po/day Morphine ER 200 mg po BID Breakthrough pain (BTP)? 1. Oxycodone / Acetaminophen 5/ tab po q4 hrs prn 2. Oxycodone IR 10 mg po q 2 hrs prn 3. Morphine IR 45 mg po q 1 hrs prn 4. Hydromorphone IR 4 mg po q 4 hrs prn * Pain Pearl * BTP IR Dose: 10-15% of 24 hour total opioid dose Interval: time to peak effect NCCN: Adult Cancer Pain v Pain Case Study PCA to Oral Opioid X = Morphine 390 mg po/day Morphine ER 100 mg 2 tabs po BID BTP: Morphine IR 45 mg (30 mg x 1.5 tab) po q1 hr prn pain Or Morphine elixir 20 mg/ml 40 mg po q1 hr prn pain Poop Prophylaxis: Senna 4 tab po BID

20 Poop Protocol Poop Protocol When to Keep SR Opioids with PCA SR opioids (act as the basal) PCA demand only (for BTP) Periprocedural Consider for sickle cell crisis

21 When to Avoid Morphine Renal Failure Majority of opioids renally cleared Active metabolites Limited studies; no RCTs No consensus on GFR (<30 ml/min) Dean: J Pain Symptom Manage 2004; King: Palliat Med 2011; Ripamonte: Annals of Onc 2012: Lee: JPM Morphine Codeine Renal Failure Hydromorphone Oxycodone Tramadol Fentanyl AVOID Cautious Dosing Safer No dose adjustment short term Potent, active metabolites cleared renally Increased risk for oversedation & neurotoxicity Poorly studied No known active renal metabolites Limited studies Dean: J Pain Symptom Manage 2004; King: Palliat Med 2011; Lee: JPM 2016.

22 Liver Failure Impaired oxidation and glucuronidation Limited studies- most extrapolated from RF High prevalence & risk of RF in cirrhosis Avoid Morphine, Codeine, Tramadol Transdermal preparations Davis: Clin Pharmacokinet 2007; Rhee: J Palliat Med 2007; Chandok: Mayo Clin Proc Avoid Morphine in renal/liver failure Consider IR preparations longer dosing intervals * Pain Pearl * Ripamonte: Annals of Onc 2012; Lee: JPM Which PCA settings would you order for 83 y/o F opioid naïve with multi-trauma s/p motor vehicle crash (nl CrCl; alert; not delirious)? Morphine basal 1 mg/hr demand 0.5 mg lockout 12 min Hydromorphone basal 0 demand 0.5 mg lockout 8 min Hydromorphone basal 0 demand 0.3 mg lockout 10 min Morphine basal 0 demand 0.5 mg lockout 10 min

23 Which PCA settings would you order for 83 y/o F opioid naïve with multi-trauma s/p motor vehicle crash (nl CrCl; alert; not delirious)? Morphine basal 0 demand 0.5 mg lockout 10 min Elderly- Opioid Reduction Require less opioid to achieve same relief Opioid sensitivity é by 50% Pain intensity ê by 10-20% each decade after age 60 Herr: Iowa City Guideline Summary NGC ; v1.0. * Pain Pearl * Initiate opioids at 25-50% lower dose than recommended for younger adults Herr: Iowa City Guideline Summary NGC Evidence Grade = B; v1.0.

24 QI: PCA Safety Checklist FOR ALL STEPS: Document exceptions to any step of the safety checklist. Address psycho-social-spiritual pain. INITIATION Patient has confirmed cognitive function physical capability Patient and family educated Document PCA indication Discontinue all other opioids CALCULATIONS GUIDELINES 40% reduction for cross tolerance when converting to another opioid For basal and demand: Is demand % of basal rate? Is RN bolus % of demand? Is demand lockout 10 minutes? Double check calculations with a palliative care team member PCA conversion verbally communicated to primary team and nurse Is patient IPC bed status? Document conversion calculations (.pccalc and.pcpca) TITRATION CALCULATIONS GUIDELINES Incremental 24 hour basal rate increase not to exceed 100% of previous basal rate For basal and demand: Is demand % of basal rate? Is RN bolus % of demand? Is demand lockout 10 minutes? Double check previous 24 hour use with a palliative care team member Double check titration calculations with a palliative care team member PCA titration verbally communicated to primary team and nurse Document titration calculations (.pcpca) TRANSITIONING Patient has confirmed GI absorption renal function appropriate for medication CALCULATIONS GUIDELINES Stable PCA use x 48 hours 40% reduction for cross tolerance when converting to another opioid Is oral PRN dose 10-15% of total daily dose? Double check calculations with a palliative care team member Patient has confirmed outpatient insurance coverage outpatient provider follow up PO conversion verbally communicated to primary team and nurse Document conversion calculations (.pccalc) PCA Safety Checklist current 24 hour dose *** = New X current ratio*** new ratio*** Total X = *** mg Total X 60% incomplete cross tolerance = *** mg Based on this calculation, patient's report of pain, and my assessment of patient, Date Basal Demand Lockout Total Use Avg per hour Recommend: **** Date Basal Demand Lockout Total Daily Avg / hour PCA table Opioid: *** Use Resources REMS NCCN Adult Cancer Pain Guidelines _guidelines.asp

25 * Pain Pearls * Adjust for incomplete cross tolerance (60%) Titrate demand dose for acute pain 25% mild pain 50% moderate pain 100% severe pain Oral BTP: 10-15% of TDD Avoid Morphine with renal / liver failure ê opioids 25-50% in elderly

Opioid Use in Serious Illness

Opioid Use in Serious Illness Opioid Use in Serious Illness Jeanie Youngwerth, MD University of Colorado School of Medicine Associate Professor of Medicine, Hospitalist Director, Palliative Care Service Associate Director, Colorado

More information

Approach to Acute Pain Management

Approach to Acute Pain Management Approach to Acute Pain Management Jeanie Youngwerth, MD University of Colorado School of Medicine Associate Professor of Medicine, Hospitalist Director, Palliative Care Service Associate Director, Colorado

More information

Opioid Pearls and Acute Pain Management

Opioid Pearls and Acute Pain Management Opioid Pearls and Acute Pain Management Jeanie Youngwerth, MD University of Colorado Denver Assistant Professor of Medicine, Hospitalist Associate Director, Colorado Palliative Medicine Fellowship Program

More information

Equianalgesic Dosing: Making Opioid Interchange Easier. Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine

Equianalgesic Dosing: Making Opioid Interchange Easier. Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine Equianalgesic Dosing: Making Opioid Interchange Easier Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine 1 Why Change Opioids? Side Effects Insufficient Pain

More information

B. Long-acting/Extended-release Opioids

B. Long-acting/Extended-release Opioids 4 Opioid tolerance is assumed in patients already taking fentanyl 25 mcg/hr OR daily doses of the following oral agents for 1 week: 60 mg oral morphine, 30 mg oxycodone, 8 mg hydromorphone, 25 mg of oxymorphone

More information

Opioid Case Studies. Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN. September 29, MFMER slide-1

Opioid Case Studies. Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN. September 29, MFMER slide-1 Opioid Case Studies Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN September 29, 2016 2015 MFMER slide-1 Disclosures Relevant Financial Relationship(s) None Off Label and/or

More information

Pharmacologic Considerations for Managing Sickle Cell Pain Claire Saadeh, PharmD, BCOP May 5, 2015

Pharmacologic Considerations for Managing Sickle Cell Pain Claire Saadeh, PharmD, BCOP May 5, 2015 Pharmacologic Considerations for Managing Sickle Cell Pain Claire Saadeh, PharmD, BCOP May 5, 2015 Table 1: Physiologic changes that occur during sickle cell pain crisis 1-3 Phase Description / Complications

More information

Opioid Conversions Mixture of Science and Art

Opioid Conversions Mixture of Science and Art Opioid Conversions Mixture of Science and Art Matthew J. Pingree, MD Assistant Professor Division of Pain Medicine Physical Medicine and Rehabilitation and Anesthesiology Mayo Clinic, Rochester Pingree.Matthew@Mayo.edu

More information

4/3/2018. Management of Acute Pain Crises. Five Mistakes I ve made and why you shouldn t

4/3/2018. Management of Acute Pain Crises. Five Mistakes I ve made and why you shouldn t Management of Acute Pain Crises Maggie O Connor, M.D. Retired Palliative Care Physician Hope is not the conviction that something will turn out well, but the certainty that something makes sense, regardless

More information

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,

More information

PAIN MANAGEMENT PGY-1. Aaron D. Storms, MD Carin van Zyl, MD Adult and Pediatric Palliative Care, LAC+USC Keck School of Medicine of USC

PAIN MANAGEMENT PGY-1. Aaron D. Storms, MD Carin van Zyl, MD Adult and Pediatric Palliative Care, LAC+USC Keck School of Medicine of USC PAIN MANAGEMENT PGY-1 Aaron D. Storms, MD Carin van Zyl, MD Adult and Pediatric Palliative Care, LAC+USC Keck School of Medicine of USC Perception Matters A builder aged 29 came to the accident and emergency

More information

Overview of Essentials of Pain Management. Updated 11/2016

Overview of Essentials of Pain Management. Updated 11/2016 0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.

More information

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117

More information

Fighting the Good Fight: How to Convert Opioids Just Right!

Fighting the Good Fight: How to Convert Opioids Just Right! Fighting the Good Fight: How to Convert Opioids Just Right! Tanya J. Uritsky, PharmD, BCPS, CPE Clinical Pharmacy Specialist - Pain Medication Stewardship Hospital of the University of Pennsylvania - Philadelphia,

More information

Opioid Conversion Guidelines

Opioid Conversion Guidelines Opioid Conversion Guidelines March 2015 Gippsland Region Palliative Care Consortium Clinical Practice Group Title Keywords Ratified Opioid, Conversion, Drug, Therapy, Palliative, Guideline, Palliative,

More information

Long Term Care Formulary HCD - 08

Long Term Care Formulary HCD - 08 1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally

More information

Pain management. Coleman Palliative Care Conference: February 2016 Josh Baru MD Stacie Levine MD

Pain management. Coleman Palliative Care Conference: February 2016 Josh Baru MD Stacie Levine MD Pain management Coleman Palliative Care Conference: February 2016 Josh Baru MD Stacie Levine MD Case #1 61 yo man with history of Stage 3 colon cancer, s/p resection and adjuvant chemotherapy with FOLFOX

More information

Interprofessional Webinar Series

Interprofessional Webinar Series Interprofessional Webinar Series Opioids in the Medically Ill: Principles of Administration Russell K. Portenoy, MD Chief Medical Officer MJHS Hospice and Palliative Care Director MJHS Institute for Innovation

More information

Opioid Rotation. Dr Bruno Gagnon, M.D., M.Sc.

Opioid Rotation. Dr Bruno Gagnon, M.D., M.Sc. Opioid Rotation Dr Bruno Gagnon, M.D., M.Sc. Associate Professor Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Université Laval Consultant in Palliative Medicine CHU de Québec-Université

More information

Arresting Pain without Getting Arrested

Arresting Pain without Getting Arrested G. Jay Westbrook, M.S., R.N., CHPN - Clinical Director Compassionate Journey: An End-of-Life Clinical & Education Service CompassionateJourney@hotmail.com 818/773-3700 Arresting Pain without Getting Arrested

More information

10 mg hydrocodone equals how much oxycodone

10 mg hydrocodone equals how much oxycodone Cari untuk: Cari Cari 10 mg hydrocodone equals how much oxycodone Posts about dilaudid 8 vs oxycodone 30 written by buyprescriptionmedication. Can you help me with the conversion of Oxycodone IR (5mg tab)

More information

Pain Management Management in Hepatic Hepatic and and Renal Dysfunction

Pain Management Management in Hepatic Hepatic and and Renal Dysfunction Pain Management in Hepatic and Renal Dysfunction Review the pharmacologic basis for medications used in pain management Identify pain medications which hshould ldbe avoided in patients with hepatic dysfunction

More information

PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST

PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST TREATMENT IN ONCOLOGY Main treatment : surgery Neoadjuvant treatment : RT, CMT Adjuvant treatment : Tx micrometastatic disease -CMT,Targeted

More information

Acute Pain Management in the Hospital Setting. Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX

Acute Pain Management in the Hospital Setting. Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX Acute Pain Management in the Hospital Setting Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX 2 What is Pain? An unpleasant sensory and emotional experience associated

More information

Amber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center

Amber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center Pharmacologic Management of Pain Amber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center Objectives Identify types of

More information

(30689) PROT Pain PCA Adult Patient Controlled Analgesia

(30689) PROT Pain PCA Adult Patient Controlled Analgesia Diagnosis Allergies Nursing Assess and Document PCA: 1. Assess and document pain rating, sedation level and respiratory rate every 2 hours; assess and document pain rating, sedation level and respiratory

More information

Lumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes.

Lumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes. Reference Guide for PACU Lumbar Fusion CLINICAL PATHWAY All patient variances to the pathway are to be circled and addressed in the progress notes. This Clinical Pathway is intended to assist in clinical

More information

BASICS OF OPIOID PRESCRIBING 10:30-11:45AM

BASICS OF OPIOID PRESCRIBING 10:30-11:45AM PROVIDING QUALITY CARE TO PAIN PATIENTS IN IOWA BASICS OF OPIOID PRESCRIBING 10:30-11:45AM ACPE UAN: 107-000-14-013-L01-P Activity Type: Application-Based 0.125 CEU/1.25hr Learning Objectives for Pharmacists:

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be

More information

RELIEVING VIRGINIA S PAIN AND SUFFERING 3:45-4:45PM

RELIEVING VIRGINIA S PAIN AND SUFFERING 3:45-4:45PM PROVIDING QUALITY CARE TO PAIN PATIENTS IN IOWA RELIEVING VIRGINIA S PAIN AND SUFFERING 3:45-4:45PM ACPE UAN: 107-000-14-016-L05-P Activity Type: Application-Based 0.1 CEU/1.0 hr Learning Objectives for

More information

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of

More information

Demystifying Opioid Conversion Calculations

Demystifying Opioid Conversion Calculations Demystifying Opioid Conversion Calculations Stephanie Cheng, PharmD, MPH, BCGP Clinical Pharmacist Hospice Pharmacy Solutions November 28, 2018 Learning Objectives After this presentation, you should be

More information

Opioids in Serious Medical Illness

Opioids in Serious Medical Illness Opioids in Serious Medical Illness Jacob J. Strand, M.D. Assistant Professor of Medicine Medical Director, Palliative Care Clinical Services Mayo Clinic Mayo Clinic Opioid Conference 2013 MFMER slide-1

More information

Oxymorphone (Opana ) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate.

Oxymorphone (Opana ) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate. Page 1 of 7 Policies Repository Policy Title Policy Number Schedule II Prior Authorization FS.CLIN.16 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on

More information

Narcotic Equivalence Converter Narcotic Route Dose Duration; Select a drug: mg Convert to: mg Adapted from Tarascon Pocket Pharmacopoeia.

Narcotic Equivalence Converter Narcotic Route Dose Duration; Select a drug: mg Convert to: mg Adapted from Tarascon Pocket Pharmacopoeia. Narcotic Equivalence Converter Narcotic Route Dose Duration; Select a drug: mg Convert to: mg Adapted from Tarascon Pocket Pharmacopoeia. Created: Monday, March 12. Online calculator to convert equianalgesic

More information

2017 Opioid Prescribing Module 401 N. Ewing St. Lancaster, Ohio (740) ~

2017 Opioid Prescribing Module 401 N. Ewing St. Lancaster, Ohio (740) ~ 2017 Opioid Prescribing Module 401 N. Ewing St. Lancaster, Ohio 43130 (740) 687-8000 ~ www.fmchealth.org Introduction The purpose of this module is to reduce the risk of adverse outcomes for adult patients

More information

Morphine er to oxycontin conversion

Morphine er to oxycontin conversion Morphine er to oxycontin conversion The Borg System is 100 % Morphine er to oxycontin conversion 17-4-2011 Conversion dose from Oxycontin 40mg 3x a day to morphine sulfate 15 mg?. Oxycontin vs morphine

More information

ANSWER # 1 PHARMACOLOGY. Methadone answers Stoltzfus 4/5/2012 METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017

ANSWER # 1 PHARMACOLOGY. Methadone answers Stoltzfus 4/5/2012 METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017 METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017 Ky Stoltzfus, MD Assistant Professor, Internal Medicine University of Kansas Medical Center ANSWER # 1 Your response might be

More information

OPIOID- INDUCED NEUROTOXICITY*

OPIOID- INDUCED NEUROTOXICITY* OPIOID- INDUCED NEUROTOXICITY* Sriram Yennu MD, MS, FAAHPM Palliative Care, Rehabilitation and Integrative Medicine U.T. M.D. Anderson Cancer Center *Slide Deck courtesy Dept PRIM MDACC PATIENT #1: MRS

More information

Dose equivalent of fentanyl patch to oxycontin

Dose equivalent of fentanyl patch to oxycontin Dose equivalent of fentanyl patch to oxycontin 10-3-2018 Detailed dosage guidelines and administration information for OxyContin (oxycodone hydrochloride). Includes dose adjustments, warnings and precautions.

More information

Review of Pain Management with Clinical and Regulatory Updates

Review of Pain Management with Clinical and Regulatory Updates Review of Pain Management with Clinical and Regulatory Updates Palliative Care Collaborative: 8 th Annual Regional Conference October 10, 2014 Michael Stellini, M.D.,M.S. Medical Director, Hospice and

More information

Pain Management Dilemmas. Five Pain Dilemmas. Barriers: Meet Loretta. Daniel Johnson, MD, FAAHPM

Pain Management Dilemmas. Five Pain Dilemmas. Barriers: Meet Loretta. Daniel Johnson, MD, FAAHPM Pain Management Dilemmas Daniel Johnson, MD, FAAHPM Kaiser Permanente University of Colorado Five Pain Dilemmas 1. Barriers to Pain Management 2. Selecting and Titrating Opioids 3. Managing PCAs 4. Using

More information

Tips for Managing Acute Pain

Tips for Managing Acute Pain Tips for Managing Acute Pain Daniel Johnson, MD, FAAHPM Kaiser Permanente University of Colorado Session Outline 1. Pseudoaddiction 2. Opioid Selection 3. PCA Titration 4. Co-Analgesics 5. Breakthrough

More information

Pain Management in Hospice and Palliative Care

Pain Management in Hospice and Palliative Care Pain Management in Hospice and Palliative Care A Case-based Approach JoAnne Nowak, M.D. Merrimack Valley Hospice Revised November 2011 Objectives Use a case study approach to stimulate discussion and illustrate

More information

Analgesics: Management of Pain In the Elderly Handout Package

Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain in the Elderly Each patient or resident and their pain problem is unique. A complete assessment should be performed

More information

1/21/14. Cancer Related Pain: Case-Based Pharmacology. Conflicts of Interest. Learning Objective

1/21/14. Cancer Related Pain: Case-Based Pharmacology. Conflicts of Interest. Learning Objective Cancer Related Pain: Case-Based Pharmacology Jeannine M. Brant, PhD, APRN, AOCN Oncology Clinical Nurse Specialist Nurse Scientist Billings Clinic Conflicts of Interest Jeannine Brant has served on the

More information

Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans

Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics 7/9/2012 Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA

More information

BJF Acute Pain Team Formulary Group

BJF Acute Pain Team Formulary Group Title Analgesia Guidelines for Acute Pain Management (Adults) in BGH Document Type Issue no Clinical guideline Clinical Governance Support Team Use Issue date April 2013 Review date April 2015 Distribution

More information

15mg oxycodone is equivalent to how much morphine

15mg oxycodone is equivalent to how much morphine 15mg oxycodone is equivalent to how much morphine The Borg System is 100 % 15mg oxycodone is equivalent to how much morphine nursing home activity director cover letter 15 mg oxycodone equal to how much

More information

Peri operative pain control. Disclosure. Objectives 9/1/2011. No current conflicts of interest

Peri operative pain control. Disclosure. Objectives 9/1/2011. No current conflicts of interest Peri operative pain control Chris Herndon, PharmD, FASHP Southern Illinois University Edwardsville Disclosure No current conflicts of interest Objectives Discuss studies evaluating the transformation of

More information

Supportive Care. End of Life Phase

Supportive Care. End of Life Phase Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of

More information

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful

More information

Management of Cancer Pain

Management of Cancer Pain Management of Cancer Pain Mihir M. Kamdar, MD Associate Director, Palliative Care Director, MGH Cancer Pain Clinic Depts of Anesthesia Pain/Palliative Care Massachusetts General Hospital None Disclosures

More information

PEDIATRIC SPINE SURGERY POST-OP PLAN - Phase:.

PEDIATRIC SPINE SURGERY POST-OP PLAN - Phase:. - Phase:. PHYSICIAN S Diagnosis Weight Allergies DETAILS Patient Care Patient Activity Bedrest Maintain Surgical Drain Maintain JP Drain, Measure Output q12h, and PRN Convert IV to INT when tolerating

More information

Pain Management in the Hospital

Pain Management in the Hospital E P E C O Pain Management in the Hospital Denise Waugh, MD FACEP FAAHPM Medical Director of Palliative Care Services Scott and White Healthcare 724-6859 Pain is a more terrible lord of mankind than even

More information

Limitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1).

Limitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.21 Subject: Subsys Page: 1 of 5 Last Review Date March 17, 2017 Subsys Description Subsys (fentanyl

More information

Objectives: What is your Definition of Pain? 8/16/2017

Objectives: What is your Definition of Pain? 8/16/2017 Safe Opioid Management for the Seriously Ill Patient Sam Perna, D.O. Objectives: MDB1 1) Participants will understand the way the body s pain system works. 2) Participants will identify the elements of

More information

Pain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine

Pain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine Pain Management Wrap-Up Chronic Care David Tauben, MD Medicine Anesthesia & Pain Medicine Objectives Understand that Pain is Complex Know how to select Rx based on Pain type Be aware that Rx only reduces

More information

Acute pain management in opioid tolerant patients. Muhammad Laklouk

Acute pain management in opioid tolerant patients. Muhammad Laklouk Acute pain management in opioid tolerant patients Muhammad Laklouk General principles An adequate review and assessment Provision of effective analgesia (including attenuation of tolerance and hyperalgesia)

More information

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM OAT Transitions - focus on microdosing Mark McLean MD MSc FRCPC CISAM DABAM Disclosures No pharmaceutical industry or other financial conflicts of interest Study Physician for research funded by Canadian

More information

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,

More information

Palliative Care for Primary Care Providers QUYNH BUI, MD MPH DECEMBER 2015

Palliative Care for Primary Care Providers QUYNH BUI, MD MPH DECEMBER 2015 Palliative Care for Primary Care Providers QUYNH BUI, MD MPH DECEMBER 2015 Objectives Define palliative care and primary palliative care Describe the rationale for providing primary palliative care in

More information

What to do when you are called to see a patient with... PAIN. Susan Merel, MD Division of General Internal Medicine July 2018

What to do when you are called to see a patient with... PAIN. Susan Merel, MD Division of General Internal Medicine July 2018 What to do when you are called to see a patient with... PAIN Susan Merel, MD Division of General Internal Medicine July 2018 Disclosures Susan Merel has no relationships with any entity producing, marketing,

More information

Use of PCA devices in Difficult Populations

Use of PCA devices in Difficult Populations Use of PCA devices in Difficult Populations Diane M. Santangelo MS RN ANP-C Stony Brook University Medical Center Acute Pain Service September 10, 2011 1 PCA technology? Why Bother? Costly Nurses complain:

More information

Beyond The Lockout Time. Kelcy Freeman, PharmD, BCPS April 20, 2017 REMEDI Pump Collaborative Spring Conference Chicago, IL

Beyond The Lockout Time. Kelcy Freeman, PharmD, BCPS April 20, 2017 REMEDI Pump Collaborative Spring Conference Chicago, IL Beyond The Lockout Time Kelcy Freeman, PharmD, BCPS April 20, 2017 REMEDI Pump Collaborative Spring Conference Chicago, IL Disclosure I am a full-time employee of Smiths Medical, global provider of medical

More information

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

Opioid Analgesics. Recommended starting dose for opioid-naïve patients Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote

More information

Reducing the risk of patient harm: A focus on opioids

Reducing the risk of patient harm: A focus on opioids Reducing the risk of patient harm: A focus on opioids New York State Partnership for Patients (NYSPFP) Initiative Regional Educational Session November 2013 1 Disclosure Matthew Fricker, Matthew Grissinger,

More information

E-Learning Module N: Pharmacological Review

E-Learning Module N: Pharmacological Review E-Learning Module N: Pharmacological Review This Module requires the learner to have read Chapter 13 of the Fundamentals Program Guide and the other required readings associated with the topic. Revised:

More information

To Infinity and Beyond! Safe and Effective Opioid Titration Strategies

To Infinity and Beyond! Safe and Effective Opioid Titration Strategies To Infinity and Beyond! Safe and Effective Opioid Titration Strategies Alexandra L. McPherson, PharmD, MPH Slide development Mary Lynn McPherson, PharmD, MA, BCPS, CPE Professor and Executive Director,

More information

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti- Page 1 of 8 Analgesia The World Health Organisation (WHO, 1990) has devised a model to assist health care professionals in the management of cancer pain. The recommendations include managing pain, by the

More information

Opioid Pain Management. John Manfredonia, DO. Disclosures. Dr. Manfredonia discloses his employment as Regional Medical Director for VistaCare

Opioid Pain Management. John Manfredonia, DO. Disclosures. Dr. Manfredonia discloses his employment as Regional Medical Director for VistaCare Opioid Pain Management John Manfredonia, DO Disclosures Dr. Manfredonia discloses his employment as Regional Medical Director for VistaCare VistaCare has provided commercial support for this activity Palliative

More information

1

1 Disclosures I do not have a vested interest in or affiliation with any corporate organization offering financial support or grant monies for this continuing education activity, or any affiliation with

More information

Long-Acting Opioid Analgesics

Long-Acting Opioid Analgesics Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required

More information

Long-Acting Opioid Analgesics

Long-Acting Opioid Analgesics Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required

More information

PAIN MANAGEMENT IN PATIENTS WITH CANCER, PART II

PAIN MANAGEMENT IN PATIENTS WITH CANCER, PART II Learning Objectives PAIN MANAGEMENT IN PATIENTS WITH CANCER, PART II MINA LEE UNIVERSITY OF WASHINGTON MEDICAL CENTER/ SEATTLE CANCER CARE ALLIANCE CLINICAL PHARMACIST, GENERAL ONCOLOGY Understand the

More information

Pitfalls in Pain Management: Practical Solutions for Hospitalists

Pitfalls in Pain Management: Practical Solutions for Hospitalists Pitfalls in Pain Management: Practical Solutions for Hospitalists Liz Merkle Hankollari, M.D. Assistant Professor Hospital Medicine/General Internal Medicine Duke University Hospital Topics for Discussion

More information

Methadone: Essential Hospice Analgesic or Too Risky for Prime Time?

Methadone: Essential Hospice Analgesic or Too Risky for Prime Time? Methadone Background Methadone: Essential Hospice Analgesic or Too Risky for Prime Time? Developed originally as an antispasmodic and later used as an analgesic, starting in late 1940 s Used extensively

More information

Pain Management in the

Pain Management in the Pain Management in the Elderly Meri Hix, PharmD, CGP, BCPS Associate Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy No conflicts of interest to declare Objectives Discuss

More information

Overcoming Opioid-Induced Oversedation: More Than Meets the Eye

Overcoming Opioid-Induced Oversedation: More Than Meets the Eye Overcoming Opioid-Induced Oversedation: More Than Meets the Eye ANCC National Magnet Conference 2013 Jeannine M. Brant, PhD, APRN, AOCN Lisa Peterson, RN-BC, BSN Health Care, Education and Research www.billingsclinic.com

More information

15 mg morphine 10 mg hydrocodone

15 mg morphine 10 mg hydrocodone Cari untuk: Cari Cari 15 mg morphine 10 mg hydrocodone 3-2-2013 Convert From CALCULATED MORPHINE EQUIVALENT BY RESOURCE: Average ( mg ) Range ( mg ) Standard Deviation of Sample ( mg ) Hydrocodone. I usually

More information

Attach patient label here. Physician Orders ADULT: Palliative Care Plan

Attach patient label here. Physician Orders ADULT: Palliative Care Plan Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase T;N, Phase: Palliative Care Phase, When to Initiate: Palliative Care Phase Admission/Transfer/Discharge Patient Status Initial

More information

Palliative and Hospice Care of the Terminally Ill Introduction

Palliative and Hospice Care of the Terminally Ill Introduction Palliative and Hospice Care of the Terminally Ill Introduction There has been an increase in life expectancy for men and women of all races to 77.6 years Leading causes of death in older patients are chronic

More information

2-ethylidene-1,5-dimethyl-3,3diphenylpyrrolidene (EDDP) Safe in stable liver disease Long acting

2-ethylidene-1,5-dimethyl-3,3diphenylpyrrolidene (EDDP) Safe in stable liver disease Long acting 2012 AAHPM & HPNA Annual Assembly March 7-10, 2012 Denver, CO Methadone the Taming of the Shrew Stefan J. Friedrichsdorf, M.D. Medical Director Department of Pain Medicine, Palliative Care & Integrative

More information

Appendix D: Drug Tables

Appendix D: Drug Tables Appendix D: Drug Tables A. Short-acting, Orally Administered Opioids Table D-1: Use of Short-acting, Orally Administered Opioids in Adults [198] Additional Maximum APAP dose: 4000 mg/d (2000 mg/d in chronic

More information

Learning Objectives. Case Example. From Coke to Pepsi or a cocktail? Rotating and adding opioids in advanced pediatric pain medicine

Learning Objectives. Case Example. From Coke to Pepsi or a cocktail? Rotating and adding opioids in advanced pediatric pain medicine From Coke to Pepsi or a cocktail? Rotating and adding opioids in advanced pediatric pain medicine Stefan J. Friedrichsdorf, MD, FAAP Associate Professor of Pediatrics, University of Minnesota Medical School

More information

July We hope that our tool will be a useful aid in your efforts to improve pain management in your setting. Sincerely, 7/14

July We hope that our tool will be a useful aid in your efforts to improve pain management in your setting. Sincerely, 7/14 July 2014 he Knowledge and Attitudes Survey Regarding Pain tool can be used to assess nurses and other professionals in your setting and as a pre and post test evaluation measure for educational programs.

More information

GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline

GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline Background Persistent pain is common, affecting around five million people in the UK. For many sufferers, pain can be frustrating and disabling,

More information

Evidence-based Best Practice in Pain Management

Evidence-based Best Practice in Pain Management Foundations in Palliative Medicine Colorado, November 2017 Evidence-based Best Practice in Pain Management Sudy Jahangiri, MD Crystal Owens, MD Continuing Education Disclosures Approval Statement: The

More information

Optimizing Your Quality of Life During Cancer Treatment: Pain & Side Effect Management

Optimizing Your Quality of Life During Cancer Treatment: Pain & Side Effect Management Optimizing Your Quality of Life During Cancer Treatment: Pain & Side Effect Management Eric Roeland, MD GI Oncology Palliative Medicine Pancreatic Cancer Patient Tool Belt Chemotherapy Surgery Pain & Symptom

More information

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure. Care of the Dying Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance covers the prescribing and management of patients

More information

The Use of Transdermal Opioids in Palliative Care. G. Whyte, P.Powell, C. Littlewood, A. Coackley, G. Leng External Reviewer/Expert : S.

The Use of Transdermal Opioids in Palliative Care. G. Whyte, P.Powell, C. Littlewood, A. Coackley, G. Leng External Reviewer/Expert : S. The Use of Transdermal Opioids in Palliative Care G. Whyte, P.Powell, C. Littlewood, A. Coackley, G. Leng External Reviewer/Expert : S. Simpson 1 Introduction Dr Graham Whyte Literature Review Dr Paula

More information

Po dilaudid versus iv dilaudid

Po dilaudid versus iv dilaudid Po dilaudid versus iv dilaudid Search IM/IV/SC 120 mg ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic an equianalgesic ratio for PO. Dilaudid official prescribing

More information

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects. Dose equivalence and switching between opioids Key Messages Switching from one opioid to another should only be recommended or supervised by a healthcare practitioner with adequate competence and sufficient

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Transmucosal Fentanyl Effective Date... 4/15/2018 Next Review Date... 4/15/2019 Coverage Policy Number... 1018 Table of Contents Coverage Policy... 1 General

More information

PEDIATRIC SPINE SURGERY POST-OP PLAN - Phase: Pediatric Spine Surgery General Orders

PEDIATRIC SPINE SURGERY POST-OP PLAN - Phase: Pediatric Spine Surgery General Orders - Phase: Pediatric Spine Surgery General Orders PHYSICIAN S Diagnosis Weight Allergies Patient Care Patient Activity Bedrest Maintain Surgical Drain Maintain JP Drain, Measure Output q12h, and PRN Convert

More information

Berkshire West Area Prescribing Committee Guidance

Berkshire West Area Prescribing Committee Guidance Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for

More information

FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA

FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,

More information

Pain Management Strategies Webinar/Teleconference

Pain Management Strategies Webinar/Teleconference Pain Management Strategies Webinar/Teleconference Barry K. Baines, MD April 16, 2009 Objectives Describe the principles of pain management. Identify considerations in the use of opioids. Describe the benefits

More information

UCSF: 150 years in the making

UCSF: 150 years in the making Securing Hospital Approval for Ketamine use on the Wards: Challenges, Outcomes and Lessons Learned Acknowledgements Mark Schumacher Ph.D.,M.D. Professor and Chief, Division of Pain Medicine Dept. of Anesthesia

More information